A Phase II Trial of Biweekly Nab-PaclitaXel in Combination with Ramcirumab for Patients with Previously Treated Advanced Gastric Cancer or Gastro-oesophageal Junction Adenocarcinoma(B-RAX trial) (JACCRO GC-09)
Latest Information Update: 16 Oct 2024
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms B-RAX
- 16 Oct 2024 Status changed from active, no longer recruiting to completed.
- 15 Apr 2023 Results published in the Targeted Oncology
- 03 Mar 2022 New trial record